Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 90

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 2
Chunk 90
---
2*
     
    Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended
  
    32.1#
     
    Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
    32.2#
     
    Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
  
    101.INS*
     
    Inline
    XBRL Instance Document
  
    101.SCH*
     
    Inline
    XBRL Taxonomy Extension Schema Document
  
    101.CAL*
     
    Inline
    XBRL Taxonomy Extension Calculation Linkbase Document
  
    101.DEF*
     
    Inline
    XBRL Taxonomy Extension Definition Linkbase Document
  
    101.LAB*
     
    Inline
    XBRL Taxonomy Extension Labels Linkbase Document
  
    101.PRE*
     
    Inline
    XBRL Taxonomy Extension Presentation Linkbase Document
  
    104
     
    Cover
    Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101)

    *
    Filed
    herewith
  
    #
    Furnished
    herewith

10

SIGNATURES

Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report
to be signed on its behalf by the undersigned, thereunto duly authorized.

    Indaptus
    Therapeutics, Inc.

    Date:
    November 12, 2025
    By:
    /s/
    Jeffrey A. Meckler

    Jeffrey
    A. Meckler

    Chief
    Executive Officer
    (Principal
    Executive Officer)

    Date:
    November 12, 2025
    By:
    /s/
    Nir Sassi

    Nir
    Sassi

    Chief
    Financial Officer
    (Principal
    Financial and Accounting Officer)

11